Filings & corporate actions
81 results filed
CSVNext results · Q2 FY27
Expected 10 Nov 2026 – 15 Nov 2026
Estimate: filed 41–46 days after quarter end, last 5 times
Dividend
₹0.90 per share · last 20 Aug 2026
2026
- 20 AugdividendDividend · ₹0.90 per share-1.9%
- 12 AugresultsResults · Q1 FY27 · consolidated and standalone+12.1%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026-0.1%NSE
- 26 MayresultsResults · Q4 FY26 · consolidated and standalone-2.2%NSE
- 10 AprshareholdingShareholding · 31 Mar 2026+2.0%NSE
- 5 FebresultsResults · Q3 FY26 · consolidated and standalone-1.2%NSE
- 13 JanshareholdingShareholding · 31 Dec 2025+0.3%NSE
Reaction to results · all yearsrose on day 0 in 33 of 76 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 12 Aug 2026 | +12.1% | +17.2% | +18.4% | 35.8× |
| Q4 FY26 | 26 May 2026 | -2.2% | -6.1% | +0.5% | 3.6× |
| Q3 FY26 | 5 Feb 2026 | -1.2% | +1.2% | -6.2% | 1.2× |
| Q2 FY26 | 13 Nov 2025 | +2.2% | +1.8% | +2.9% | 1.7× |
| Q1 FY26 | 12 Aug 2025 | -11.1% | -13.6% | -17.1% | 8.6× |
| Q4 FY25 | 19 May 2025 | -6.6% | -0.6% | -1.1% | 1.5× |
| Q3 FY25 | 11 Feb 2025 | +1.0% | -9.3% | -22.7% | 1.8× |
| Q2 FY25 | 12 Nov 2024 | +1.7% | +2.7% | +3.9% | 4.4× |
| Q1 FY25 | 14 Aug 2024 | +14.0% | +22.4% | +42.5% | 9.1× |
| Q4 FY24 | 30 May 2024 | +1.4% | +6.6% | +11.8% | 1.6× |
| Q3 FY24 | 13 Feb 2024 | +0.4% | -1.1% | -15.8% | 1.4× |
| Q2 FY24 | 10 Nov 2023 | +5.2% | +13.2% | +31.7% | 4.7× |
| Q1 FY24 | 11 Aug 2023 | -3.6% | -4.2% | -10.4% | 1.4× |
| Q4 FY23 | 31 May 2023 | +5.2% | +10.2% | +14.0% | 6.5× |
| Q3 FY23 | 13 Feb 2023 | +3.9% | +7.9% | +0.1% | 2.2× |
| Q2 FY23 | 15 Nov 2022 | +1.6% | +5.3% | +19.2% | 1.7× |
| Q1 FY23 | 14 Aug 2022 | +6.0% | +2.1% | +5.7% | 4.6× |
| Q4 FY22 | 31 May 2022 | 0.0% | -2.7% | -9.3% | 0.6× |
| Q3 FY22 | 11 Feb 2022 | -5.8% | -7.7% | -10.7% | 1.6× |
| Q2 FY22 | 10 Nov 2021 | -6.5% | -12.2% | -11.1% | 4.4× |
| Q1 FY22 | 11 Aug 2021 | -6.0% | -6.9% | -8.4% | 2.5× |
| Q4 FY21 | 31 May 2021 | -0.4% | -6.5% | +17.9% | 0.4× |
| Q3 FY21 | 8 Feb 2021 | -5.0% | -9.7% | -5.3% | 1.5× |
| Q2 FY21 | 6 Nov 2020 | -0.6% | -2.6% | +16.8% | 1.1× |
| Q1 FY21 | 4 Aug 2020 | +4.9% | +11.5% | +8.9% | 0.1× |
| Q4 FY20 | 2 Jun 2020 | +9.9% | +10.8% | +28.5% | 0.5× |
| Q3 FY20 | 11 Feb 2020 | -0.7% | -4.7% | -38.4% | 1.2× |
| Q2 FY20 | 13 Nov 2019 | -3.0% | +1.0% | -10.5% | 1.5× |
| Q1 FY20 | 12 Aug 2019 | -8.8% | -16.5% | -7.1% | 0.5× |
| Q4 FY19 | 29 May 2019 | -7.2% | -8.2% | -17.6% | 2.7× |
| Q3 FY19 | 13 Feb 2019 | +1.0% | -2.9% | +3.8% | 0.6× |
| Q2 FY19 | 28 Nov 2018 | -2.8% | -7.7% | -9.2% | 0.4× |
| Q1 FY19 | 20 Aug 2018 | +1.9% | +11.0% | +8.5% | 0.8× |
| Q4 FY18 | 26 Jun 2018 | -5.5% | +2.7% | -5.0% | 0.6× |
| Q3 FY18 | 14 Feb 2018 | -2.8% | -6.6% | -12.7% | 0.5× |
| Q2 FY18 | 22 Nov 2017 | -0.4% | -4.9% | -3.0% | 0.4× |
| Q1 FY18 | 21 Aug 2017 | -0.4% | +7.2% | +22.9% | 0.7× |
| Q4 FY17 | 17 Jun 2017 | -0.6% | -5.2% | -2.0% | 0.4× |
| Q3 FY17 | 8 Feb 2017 | +0.5% | -1.4% | +20.2% | 1.7× |
| Q2 FY17 | 18 Nov 2016 | -0.9% | -0.2% | -1.4% | 0.5× |
| Q1 FY17 | 29 Aug 2016 | +1.6% | +2.6% | +21.0% | 1.0× |
| Q4 FY16 | 30 May 2016 | -6.3% | -10.2% | -4.7% | 2.0× |
| Q3 FY16 | 14 Feb 2016 | -9.1% | -14.8% | +2.3% | 1.1× |
| Q2 FY16 | 17 Nov 2015 | +1.4% | +6.6% | -1.3% | 0.8× |
| Q1 FY16 | 10 Aug 2015 | -0.9% | -1.3% | -25.5% | 0.7× |
| Q4 FY15 | 3 Jun 2015 | +0.5% | -1.9% | +21.0% | 0.7× |
| Q3 FY15 | 9 Feb 2015 | +3.4% | +12.4% | +5.4% | 1.5× |
| Q2 FY15 | 5 Nov 2014 | -3.8% | -4.6% | -9.9% | 0.9× |
| Q1 FY15 | 14 Aug 2014 | +4.2% | +17.8% | +38.6% | 4.6× |
| Q4 FY14 | 31 May 2014 | -2.0% | +31.5% | +32.7% | 0.5× |
| Q3 FY14 | 4 Feb 2014 | -2.4% | -9.9% | -9.4% | 1.3× |
| Q2 FY14 | 6 Nov 2013 | +5.0% | +17.4% | +32.8% | 2.1× |
| Q1 FY14 | 29 Jul 2013 | -4.7% | -23.6% | -31.9% | 1.0× |
| Q4 FY13 | 4 Jun 2013 | +4.8% | +8.6% | +56.2% | 1.0× |
| Q3 FY13 | 18 Feb 2013 | -2.7% | +11.0% | +9.6% | 0.7× |
| Q2 FY13 | 15 Nov 2012 | +3.1% | +18.7% | +115.6% | 1.7× |
| Q1 FY13 | 22 Aug 2012 | -3.3% | +3.3% | 0.0% | 1.4× |
| Q4 FY12 | 6 Jun 2012 | +3.6% | 0.0% | +3.6% | 1.1× |
| Q3 FY12 | 13 Feb 2012 | +4.7% | -4.7% | -16.3% | 1.7× |
| Q2 FY12 | 22 Nov 2011 | -8.1% | +8.1% | -5.4% | 0.9× |
| Q1 FY12 | 16 Aug 2011 | -4.0% | -8.0% | -8.0% | 0.5× |
| Q3 FY11 | 15 Feb 2011 | 0.0% | -3.3% | -16.4% | 0.8× |
| Q2 FY11 | 15 Nov 2010 | -12.8% | -14.9% | -25.5% | 3.1× |
| Q1 FY11 | 12 Aug 2010 | -1.2% | -1.2% | -3.7% | 0.6× |
| Q4 FY10 | 7 May 2010 | +4.3% | -3.3% | -10.9% | 0.8× |
| Q3 FY10 | 29 Jan 2010 | 0.0% | -7.1% | -10.7% | 0.4× |
| Q2 FY10 | 30 Oct 2009 | -4.1% | +4.1% | 0.0% | 1.4× |
| Q1 FY10 | 31 Jul 2009 | +1.0% | +3.0% | +32.0% | 0.5× |
| Q3 FY09 | 31 Jan 2009 | -4.1% | -8.3% | -11.6% | 0.6× |
| Q2 FY09 | 31 Oct 2008 | +5.3% | +34.5% | -0.9% | 1.7× |
| Q1 FY09 | 31 Jul 2008 | +2.3% | +1.8% | -6.1% | 1.1× |
| Q4 FY08 | 30 Apr 2008 | -0.4% | -9.2% | -15.5% | 0.6× |
| Q3 FY08 | 1 Feb 2008 | +4.0% | +19.3% | +18.4% | 0.5× |
| Q2 FY08 | 31 Oct 2007 | +4.8% | +20.3% | +41.6% | 1.0× |
| Q1 FY08 | 31 Jul 2007 | -1.8% | -0.9% | -8.3% | 1.6× |
| Q4 FY07 | 30 Apr 2007 | -3.4% | -5.2% | -8.6% | 0.7× |
| Average | -0.4% | +1.1% | +3.3% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+35.6%
Profit YoY+173.9%
Interest cost YoY+114.0%
Revenue QoQ-1.8%
Profit QoQ+7.0%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +18.3% | +18.2% | +19.1% | +17.9% | +17.4% | +17.8% |
| Profit | +25.0% | +23.7% | +29.7% | +15.7% | +23.4% | +31.2% |
Key data
CSVOpen332.75
Day range322.20 – 341.95
52-week range155.00 – 350.95
From 52w high-7.6%
RSI (14)49.4
ATR (14)14.58
Volume31.13L
Avg volume (20D)24.24L
Rel volume1.28×
Volatility (1Y)42.9%
Turnover₹101.0Cr
SMA 50 / 200312.68 / 229.29
Delivery percentage
Latest · 6 Oct 202647.2%
20-day avg39.9%
1-year avg42.0%
Percentile (own history)60th
Range10.0–100.0%
Sessions1,731
Over the last 20 sessions MARKSANS settled 39.9% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 42.0%, so recent sessions are running 2.1 points lower than usual. The latest session ranks higher than 60% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -2.19% | -2.16% | -2.35% | +24.20% | +92.92% | +97.35% |
Valuation
CSVMarket cap₹14,701 Cr
P/E (TTM)28.2
EPS (TTM)11.50
Shares outstanding45.32Cr
Listed21 Jan 2002
Ownership
CSVPromoter43.87%
Promoter Δ QoQ0.00 pp
Public56.13%
FII17.47%
DII6.19%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 720.4 | 754.4 | 856.1 | 840.8 |
| YoY chg | +12.2% | +10.6% | +1108.4% | +35.6% |
| Net profit (₹ Cr) | 99.1 | 113.7 | 149.0 | 159.4 |
| YoY chg | +1.4% | +8.2% | +1542.7% | +173.9% |
| Net margin | 13.8% | 15.1% | 17.4% | 19.0% |
| EPS | 2.17 | 2.50 | 3.27 | 3.47 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 43.87% · public 56.13%2021-092026-06
- Promoter
- Public and others
- Promoter
- 43.87%
- Public
- 56.13%
- Promoter change
- 0.00 pp
- Filed
- 20 Jul 2026
- FII
- 17.47%
- DII
- 6.19%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 531.2 | 586.1 | 560.0 | 590.6 | 641.9 | 681.8 | 70.8 | 620.0 | 720.4 | 754.4 | 856.1 | 840.8 | |
| Other income | 19.0 | 4.8 | 16.5 | 14.9 | 11.1 | 27.8 | 1.7 | 5.6 | 21.6 | 20.1 | 35.2 | 25.4 | |
| Total income | 550.2 | 590.9 | 576.5 | 605.6 | 653.0 | 709.7 | 72.5 | 625.6 | 742.0 | 774.6 | 891.3 | 866.2 | |
| Total expenses | 436.5 | 478.3 | 476.3 | 485.5 | 528.4 | 566.4 | 60.9 | 549.0 | 608.6 | 623.9 | 691.3 | 659.6 | |
| └ Finance costs | 1.6 | 3.2 | 4.8 | 2.9 | 2.6 | 2.7 | 0.3 | 6.1 | 5.8 | 5.9 | 6.3 | 7.0 | |
| └ Depreciation | 17.6 | 22.0 | 21.1 | 20.4 | 19.5 | 20.7 | 2.3 | 23.1 | 26.9 | 24.3 | 24.3 | 24.9 | |
| Profit before tax | 113.8 | 112.7 | 100.3 | 120.0 | 124.6 | 143.3 | 11.6 | 76.6 | 133.3 | 150.6 | 200.0 | 206.6 | |
| Tax expense | 29.9 | 29.7 | 22.6 | 31.0 | 26.8 | 38.2 | 2.5 | 18.4 | 34.2 | 36.9 | 51.0 | 47.2 | |
| Net profit | 83.9 | 83.0 | 77.6 | 89.1 | 97.8 | 105.1 | 9.1 | 58.2 | 99.1 | 113.7 | 149.0 | 159.4 | |
| EPS | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 | 3.47 | |
| Net margin | 15.78% | 14.15% | 13.86% | 15.08% | 15.23% | 15.41% | 12.81% | 9.39% | 13.76% | 15.07% | 17.41% | 18.96% | |
| PBT margin | 21.42% | 19.22% | 17.91% | 20.32% | 19.41% | 21.01% | 16.39% | 12.35% | 18.51% | 19.97% | 23.36% | 24.57% | |
| Tax rate | 26.30% | 26.36% | 22.57% | 25.79% | 21.54% | 26.66% | 21.85% | 24.02% | 25.65% | 24.52% | 25.48% | 22.83% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 12 Aug 2026.
MARKSANS at a glance
- MARKSANS closed at ₹324.4 on 6 Oct 2026, -2.19% on the day, +97.3% over one year, 7.6% below its 52-week high of ₹350.95.
- Delivery was 47.2% of traded quantity on 6 Oct 2026, the 60th percentile of its own 1,731 sessions with a reading (20-session average 39.9%, 1-year average 42.0%).
- Market capitalisation is ₹14,701 crore at a trailing P/E of 28.2 (trailing EPS ₹11.5).
- Q1 FY27 results (consolidated, filed 12 Aug 2026): revenue ₹841 crore (+35.6% year on year), net profit ₹159 crore (+173.9%); the price moved +12.1% on the first session after.
- Promoters held 43.87% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 10 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE750C01026
SeriesEQ
Listed21 Jan 2002
History from14 Nov 2005
Sessions5,177
Turnover rank#356
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE